Clinical Trial

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Study acronym: EXPEL PANC
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-09-26; most recent amendment 2026-02-10.
Status change: Recruiting → Active, Not Recruiting 2025-09-20
Status change: Not Yet Recruiting → Recruiting 2023-06-20
Trial Details
NCT Number NCT05558982
Lead Sponsor Georgetown University
Collaborators: BioXcel Therapeutics Inc, Merck Sharp & Dohme LLC
Conditions Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment 22 participants
Start Date 2023-08-16
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-12